HLA Antibody Specificity Analysis (Scheme 3)
UKAS Schedule of Accreditation, Accredited to ISO/IEC 17043:2010 Provider 8351
HLA Antibody Specification
PURPOSE OF PROGRAMME:
To assess the laboratory's ability to determine the component HLA specificity or specificities in the antisera using all methods the laboratory employs for clinical samples.
|HLA Antibodies||HLA antibody specificities|
MATERIAL PROVIDED: Serum
DISTRIBUTIONS PER YEAR: 2
SAMPLES PER DISTRIBUTION: 5
FREQUENCY OF DISTRIBUTION: As per Distribution Timetable
PROGRAMME OF ANALYSIS:
Results should be submitted via online data entry. Results are expected to be returned within the specified reporting period (please refer to results deadline for each distribution on the UK NEQAS for H&I website or Participants Manual). The majority of UK NEQAS for H&I schemes are assessed on a consensus basis, therefore samples are distributed with the assigned value not being determined. Where a reference result is used, this testing is performed alongside or after the close of the EQA scheme. For these reasons UK NEQAS for H&I is unable to disclose results early.
Class I and Class II IgG specificities will be assessed independently. Consensus presence of a specificity is determined by at least 75% of laboratories agreeing the specificity. Consensus absence of a specificity is determined by at least 95% of laboratories agreeing the absence of the specificity
Satisfactory performance is testing ten serum samples and getting at least 75% of specificities in agreement with the consensus findings in a year.
PERSISTENT POOR PERFORMANCE:
Laboratories not meeting the Satisfactory Performance criteria are deemed to have Unsatisfactory Performance and must complete a root cause, corrective and preventative action form.
Histocompatibility & Immunogenetics
The External Quality Assessment Scheme for Histocompatibility and Immunogenetics was founded in 1975 by Dr Heather Dicks and Dr Colin Entwistle at the National Tissue Typing and Reference Laboratory (NTTRL) based at Southmead Hospital in Bristol. In 1989 the Service became known as the UK National External Quality Assessment Service for Histocompatibility and Immunogenetics with Dr Peter Klouda as the service director and Mr Terry Ray as the service manager. The service relocated to a new host organisation in September 2000. UK NEQAS for Histocompatibility and Immunogenetics is now part of the Welsh Blood Service.